Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

The person depicted is a model used for illustrative purposes only.

Watch the Implementing MENVEO Into Your Practice Video

MENVEO is a solution for intramuscular injection supplied in 2 vials the contents of which must be combined prior to administration1:

  • MenA lyophilized conjugate vaccine component
  • MenCYW-135 liquid conjugate vaccine component

After reconstitution, a single dose of MENVEO is 0.5 mL1

Please note that neither component should be given alone.

MENVEO can be reconstituted in 3 steps: PULL, MIX, and SHAKE1

 

Watch the MENVEO Preparation Video

References

  1. Prescribing Information for MENVEO.
  2. Pelton SI. Meningococcal disease awareness: clinical and epidemiological factors affecting prevention and management in adolescents. J Adolesc Health. 2010;46(2):S9-S15.
  3. Meningococcal vaccines for preteens, teens. Centers for Disease Control and Prevention website. http://www.cdc.gov/features/meningococcal/. Updated April 18, 2016. Accessed October 6, 2017.
  4. Meningococcal disease. In: Hamborsky J, Kroger A, Wolfe C, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Washington, DC: Public Health Foundation; 2015:231-245. http://www.cdc.gov/vaccines/pubs/pinkbook/mening.html. Accessed October 6, 2017.
  5. Slack R, Hawkins KC, Gilhooley L, Addison GM, Lewis MA, Webb NJA. Long-term outcome of meningococcal sepsis-associated acute renal failure. Pediatr Crit Care Med. 2005;6(4):477-479.
  6. Vyse A, Anonychuk A, Jäkel A, Wieffer H, Nadel S. The burden and impact of severe and long-term sequelae of meningococcal disease. Expert Rev Anti Infect Ther. 2013;11(6):597-604.
  7. MacNeil J, Cohn A. Meningococcal disease. In: Roush SW, Baldy LM, eds. Manual for the Surveillance of Vaccine-Preventable Diseases. 5th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2011. http://www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.pdf. Accessed October 6, 2017.
  8. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403.
  9. Centers for Disease Control and Prevention website. Active bacterial core surveillance report, emerging infections program network, Neisseria meningitidis, 2005-2014. http://www.cdc.gov/abcs/reports-findings/surv-reports.html. Accessed October 6, 2017.
  10. Pichichero ME. Booster vaccinations: can immunologic memory outpace disease pathogenesis? Pediatrics. 2009;124(6):1633-1641.

INDICATION

MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons aged 2 months through 55 years. MENVEO does not prevent N. meningitidis serogroup B infections.

IMPORTANT SAFETY INFORMATION FOR MENVEO

  • Severe allergic reaction (eg, anaphylaxis) after a previous dose of MENVEO, any component of this vaccine, or any other CRM197, diphtheria toxoid, or meningococcal-containing vaccine is a contraindication to administration of MENVEO
  • Appropriate medical treatment must be available should an acute allergic reaction, including an anaphylactic reaction, occur following administration of MENVEO
  • Syncope, sometimes resulting in falling injury associated with seizure-like movements, has been reported following vaccination with MENVEO. Vaccinees should be observed for at least 15 minutes after vaccine administration to prevent and manage syncopal reactions
  • Safety and effectiveness of MENVEO have not been evaluated in immunocompromised persons. If MENVEO is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the expected immune response may not be obtained
  • Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to administer MENVEO to subjects with a known history of GBS should take into account the potential benefits and risks
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. The decision about when to administer an intramuscular vaccine, including MENVEO, to an infant born prematurely should be based on consideration of the individual infant’s medical status and the potential benefits and possible risks of vaccination
  • In clinical trials evaluating a primary vaccination dose or series, common solicited adverse reactions with MENVEO among children initiating vaccination at 2 months of age and receiving the four-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, vomiting, and diarrhea. Common solicited adverse reactions among children initiating vaccination at 7 months through 23 months of age and receiving the two-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, and diarrhea. Common solicited adverse reactions among children aged 2 years through 10 years who received MENVEO were injection-site pain, erythema, irritability, induration, sleepiness, malaise, and headache. Common solicited adverse reactions among adolescents and adults aged 11 through 55 years who received a single dose of MENVEO were pain at the injection site, headache, myalgia, malaise, and nausea. Some events were severe. In a clinical trial evaluating booster dose vaccination among adolescents and adults aged 15 through 55 years, similar rates of solicited adverse reactions were observed following a single booster dose. Common solicited adverse reactions were pain at the injection site and fatigue
  • Vaccination with MENVEO may not result in protection in all vaccine recipients

All trademarks are the property of their respective owners.